FDA Greenlights Pluvicto for Earlier Prostate Cancer, Doubling Eligible Patients

The FDA has expanded Novartis's blockbuster radioligand therapy Pluvicto to treat PSMA-positive metastatic hormone-sensitive prostate cancer. This moves the drug from late-stage, castration-resistant disease into earlier treatment lines, nearly doubling the eligible U.S. patient pool. The decision was supported by a 33% reduction in risk of progression or death when Pluvicto was added to standard androgen receptor inhibitors. It is now the only PSMA-targeted agent...